Evidence map›Paper›PMID 35484401›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

Lower dACC glutamate in cannabis users during early phase abstinence.

Chun S Zuo, Katherine A Davis, Scott E Lukas

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Test-retest precision of brain metabolites in healthy participants usingQuantitative imaging in medicine and surgery · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Chronic cannabis use alters dACC-striatal glutamatergic balance.Pharmacology, biochemistry, and behavior · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Chun S ZuoMcLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, 02478, USA. chun@mclean.harvard.edu.
Katherine A DavisMcLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, 02478, USA.
Scott E LukasMcLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, 02478, USA.
Harvard University · USImaging Center · US

Funding

Brain Neurochemical Profile During Marijuana AbstinenceR21DA041574 · NIDA · MCLEAN HOSPITAL · PI ZUO, CHUN S · 2017 to 2018
$449k
NIDA NIH HHS R21 DA041574
6 · The paper itself

Abstract

Glutamate plays an important role in continued use of and relapse to abused substances. However, its involvement in cannabis withdrawal is still unclear. We hypothesize that regional glutamate is associated with the cannabis withdrawal syndrome and recently examined possible association of glutamate with cannabis withdrawal, using magnetic resonance spectroscopy (MRS), in non-treatment-seeking cannabis users. We recruited 26 frequent cannabis users and 11 age-matched non-using controls. Of the 37, 20 users (8f/12m) and 10 controls (5f/5m) completed a verified 21-day abstinence protocol. Dorsal anterior cingulate cortex (dACC) glutamate and γ-amino butyric acid (GABA) were measured with proton MRS at baseline and on abstinent days 7 and 21 in conjunction with measures of cannabis withdrawal and craving (MCQ), sleep difficulties (PSQI) and mood state. We used ANOVA to examine group differences in glutamate and GABA from baseline through day 21 and used linear regression to evaluate correlations between intra-individual glutamate and withdrawal symptoms. We found that self-reported anxiety severity (HAMA) was correlated with urinary THC/Cr ratios at baseline (r = 0.768, p = 0.000076) and abstinent day 7 (r = 0.5636, p = 0.0097), dACC glutamate was significantly lower in the users compared with the controls from baseline through day 21 (F = 5.90, p = 0.022), changes in glutamate between baseline and abstinent day 21 had a significantly negative correlation with corresponding changes in craving (r = -0.72, p = 0.005) after adjusting for age, consumption of alcohol/cigarettes, sleep difficulties, and urinary THC levels. These findings provide preliminary evidence that dACC glutamate is associated with the cannabis withdrawal syndrome.

Indexed as

CannabisHallucinogensSleep Initiation and Maintenance DisordersSubstance Withdrawal SyndromeCannabinoid Receptor AgonistsDronabinolgamma-Aminobutyric AcidGlutamic AcidGyrus CinguliHumansProtonsCannabinoid Receptor AgonistsDronabinolgamma-Aminobutyric AcidGlutamic AcidHallucinogensProtons

Identifiers

PMID35484401
PMCPMC9485248
OpenAlexW4224981148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.